­Sent by email to: [XXXXXXXXXXXXXXXXXXXXX](mailto:richard.cowan5@nhs.net)X

XXXXXXXXX XXXXXXX XXXXX

The UK Cutaneous Lymphoma Group

19 April 2021

Dear XXXXXXXXX XXXXXXX XXXXX

**Re: Final Appraisal Document –** **Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]**

Thank you for your note of 13 April 2021, responding to my initial scrutiny letter. This letter represents my final decision on initial scrutiny.

***Ground 2:******the recommendation is unreasonable in the light of the evidence submitted to NICE***

**Points 1-4**

Already accepted as valid.

**Point 5 – that the FAD did not take into account a distinct cohort of patients in the MAVORIC trial with an aggressive leukaemic CTCL variant, Sezary syndrome, who did obtain an excellent clinical benefit from mogamulizumab therapy.**

Thank you for your further elaboration of this point. I agree that it is a valid appeal point.

I have agreed that all of the points you have raised are valid appeal points. NICE will now contact you to make arrangements for an oral appeal hearing, which is likely to be conducted remotely. Your appeal points will be shared in advance with any co-appellants, and you will in turn receive the appeal points that have been accepted from any co-appellants, to help with preparing for the appeal day. The chair of the appeal panel is likely to want to group points that raise similar issues to be taken together, so that the day can be conducted most effectively, and may be in touch in this regard.

Ordinarily appeals are conducted on the basis of the appellants written appeal letters, and the material generated during the appraisal process. Use of additional written material is discouraged, and the panel cannot receive any new evidence. If, exceptionally, you feel there is written material that will not be before the panel that you would wish to rely on you must let NICE know by return of letter, indicating what the material is, why it is desirable to submit it, and when it will be available, by no later than **Monday 26 April 2021**. Please note that the appeal panel cannot accept papers that are tabled late or ad hoc, as this affects the preparation of the panel and other parties for the appeal.

Many thanks

Yours sincerely

Tim Irish

Vice Chair

National Institute for Health and Care Excellence